Intract Announces Appointment of Srini Ramanathan, PhD, Chief Development Officer at Roivant Sciences as a Key Product Development Advisor

London, United Kingdom – Intract Pharma (‘‘Intract’’) today announced the appointment of Srini Ramanathan, Ph.D. as a product development advisor. Dr Ramanathan brings a wealth of drug development expertise across a wide range of diseases and will provide strategic development expertise to Intract’s team as the company moves forward towards taking novel orally delivered antibody therapeutics in immunology towards the clinic. 

Dr Ramanathan is Chief Development Officer at Roivant overseeing R&D for diligence around business opportunities, new company creation and stand-up. He was previously at Horizon Therapeutics where he served as Senior Vice President of Research and Development Sciences and Site Head of the South San Francisco office. At Horizon, Dr. Ramanathan was responsible for various scientific functions across discovery and development supporting pipeline expansion, regulatory submissions, and business development activities. Earlier in his career, he served in leadership roles at AbbVie and Gilead Sciences. He has made significant contributions to the global approval of several medicines in virology, oncology, and autoimmune disease, and has presented/published his research extensively.

‘’We are delighted to have Srini join us as an advisor. With his vast experience in R&D and drug development, Srini will be a great addition as our team works towards taking our lead oral anti-TNFα mAb towards the clinic together with Tharimmune, as well as expand our pipeline of next generation of oral biologics’’

Vipul Yadav, CEO Intract Pharma. 

‘’I am excited to advise the Intract team in developing new treatments with their innovative and unique oral antibody/biologics delivery technology’’ 

Dr Ramanathan

About Intract Pharma

Intract Pharma is a biopharmaceutical company developing disruptive oral antibody delivery solutions to significantly improve the efficacy and safety of emerging and established protein therapeutics, as well as improve patient experience and outcomes in inflammation and immunology indications. Its platform leverages the advantage of precision targeting of large proteins and antibodies to the colon, while also protecting the biologics from enzymatic breakdown, allowing tissue/systemic uptake to create next-generation oral antibody medicines. For more information visit: www.intractpharma.com  

About Roivant

Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch ‘Vants’ – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com.

Intract Contact

Dr Vipul Yadav

CEO

[email protected]